PHP
SRPT icon

Parkman Healthcare Partners’s Sarepta Therapeutics SRPT Stock Holding History

Parkman Healthcare Partners’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-35,314
Closed -$4.58M – 94
2022
Q4 		$4.58M Buy
+35,314
New +$4.09M 1.22% 34

Other funds holding SRPT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Parkman Healthcare Partners's SRPT Position: Q1 2023 in Review

Parkman Healthcare Partners sold out of Sarepta Therapeutics (SRPT) in Q1 2023, closing a stake of 35,314 shares — an estimated $4.58M sold.

Parkman Healthcare Partners first reported a position in SRPT in Q4 2022 and held it in 1 quarter. The position peaked at $4.58M in Q4 2022. 426 funds tracked by Wall St. Rank hold SRPT as of Q1 2023.

  • Parkman Healthcare Partners reported no remaining Sarepta Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Parkman Healthcare Partners sold 35,314 Sarepta Therapeutics shares in Q1 2023, an estimated $4.58M.
  • Parkman Healthcare Partners first reported a position in Sarepta Therapeutics in Q4 2022 and held it in 1 quarter.
  • Parkman Healthcare Partners's Sarepta Therapeutics position peaked at $4.58M in Q4 2022.
  • 426 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2023.

Based on Parkman Healthcare Partners's 13F filing for Q1 2023, filed 12 May 2023.